ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Eightcap Launches CoinDesk 20 Index CFD, Bringing Institutional-Grade Crypto Access to Retail Traders

Broker News
01 July 2025 12:20PM

In a landmark move for the digital asset industry, Australian fintech firm Eightcap has unveiled a new Contract for Difference (CFD) product based on the CoinDesk 20 Index (CD20)—a benchmark that tracks the performance of the most liquid and representative cryptocurrencies. This launch marks the first time the CD20 Index is available as a regulated CFD product to retail traders globally.

What Is the CoinDesk 20 Index?

The CoinDesk 20 Index is a carefully curated basket of the top 20 digital assets by liquidity and market representation. It serves as a reliable benchmark for institutional and retail investors seeking exposure to the broader crypto market. By offering a weighted performance snapshot, the index provides a diversified view of the digital asset landscape, helping traders make informed decisions.

Eightcap’s Strategic Leap

Eightcap’s decision to offer the CD20 as a CFD reflects its commitment to bridging the gap between traditional finance (TradFi) and the crypto ecosystem. CFDs allow traders to speculate on price movements without owning the underlying asset, making them a flexible and accessible tool for retail investors.

The CD20 CFD is available in both fiat and USDT pairs, and is offered as an over-the-counter (OTC) derivatives product. This means traders can access the product outside of centralized exchanges, with pricing and execution handled directly by Eightcap.

Global Reach and Regulatory Strength

Headquartered in Melbourne, Eightcap holds regulatory licenses across Australia, the UK, the EU, and the Bahamas, positioning it as a trusted provider in the global financial landscape. Its infrastructure, known as Eightcap Embedded, enables seamless integration with fintech and crypto platforms via open APIs, allowing partners to offer regulated derivatives directly within their environments.

The CD20 CFD is also tradable via TradingView, one of the world’s most popular charting and trading platforms. This integration ensures that millions of traders can access the product through familiar interfaces, enhancing usability and reach.

Industry Voices

Patrick Murphy, Chief Commercial Officer at Eightcap, emphasized the significance of the launch:

“Partnering with CoinDesk Indices allows us to deliver a world-first regulated product that meets the evolving needs of both crypto-native and traditional trading platforms.”

Alan Campbell, President of CoinDesk Indices, added:

“The marketplace needs a diversified benchmark for analysis and financial products. We are excited Eightcap will unlock a new distribution path of opportunity, while bringing regulatory standards to the forefront.”

Expanding Horizons

Beyond the CD20 CFD, Eightcap plans to roll out USDT-denominated derivatives across traditional asset classes such as equities, indices, forex, and commodities. These products will be priced and executed using Bitfinex markets, enabling stablecoin-native users to access traditional financial instruments with familiar on-chain liquidity.

The product was officially unveiled at Consensus 2025 in Toronto, during a session titled Unlocking Regulated Market Access at Scale – A New Standard for Crypto Derivatives. The launch was also featured on CoinDesk Live, where Eightcap’s leadership discussed the implications of regulated crypto benchmarks for global retail markets.

For a detailed comparison of brokers, you can check ADVFN Broker Listing.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.